Sign in Register

Drug class

Antiviral - Influenza A

The exact phrase "Antiviral - Influenza A" is an administrative formulary or compendial categorization rather than a formal FDA Established Pharmacologic Class (EPC). Read more about Antiviral - Influenza A

43 drugs in this class 30 manufacturers

Related classes & indications

Antimalarial DrugsAnti-infectives · 223 prescription drugs Antiprotozoal AgentsAnti-infectives · 102 prescription drugs Influenza Due To Influenza Virus Type ATop indication · 4 prescription drugs

Showing 10–18 of 43 drugs

Sort

OSELTAMIVIR PHOSPHATE

ANTIVIRAL - INFLUENZA A · INFLUENZA ·+1

MACLEODS PHARMA

OSELTAMIVIR PHOSPHATE

ANTIVIRAL - INFLUENZA A · INFLUENZA ·+1

ALVOGEN INC

OSELTAMIVIR PHOSPHATE

ANTIVIRAL - INFLUENZA A · INFLUENZA ·+1

ZYDUS PHARMACEU

OSELTAMIVIR PHOSPHATE

ANTIVIRAL - INFLUENZA A · INFLUENZA ·+1

CAMBER PHARMACE

OSELTAMIVIR PHOSPHATE

ANTIVIRAL - INFLUENZA A · INFLUENZA ·+1

LUPIN PHARMACEU

OSELTAMIVIR PHOSPHATE

ANTIVIRAL - INFLUENZA A · INFLUENZA ·+1

LUPIN PHARMACEU

OSELTAMIVIR PHOSPHATE

ANTIVIRAL - INFLUENZA A · INFLUENZA ·+1

Amneal Pharmaceuticals

OSELTAMIVIR PHOSPHATE

ANTIVIRAL - INFLUENZA A · INFLUENZA ·+1

STRIDES PHARMA

XOFLUZA (baloxavir marboxil)

ANTIVIRAL - INFLUENZA A · INFLUENZA ·+1

GENENTECH

Filter & compare in the drug finder → Opens the drug finder with Antiviral - Influenza A preselected. Add indication or manufacturer filters there.

About Antiviral - Influenza A.

The exact phrase "Antiviral - Influenza A" is an administrative formulary or compendial categorization rather than a formal FDA Established Pharmacologic Class (EPC).

In clinical practice and standard pharmacologic taxonomy, these therapeutics encompass anti-influenza agents that inhibit influenza virus replication, historically divided between selective viral M2 proton-channel blockers (adamantanes, active only against influenza A) and broad-spectrum influenza antivirals like neuraminidase inhibitors and cap-dependent endonuclease inhibitors (active against both influenza A and B).

These agents are indicated for the prevention and treatment of acute uncomplicated influenza viral infections and the management of epidemic outbreaks, although the clinical utility of M2 blockers has been largely superseded by widespread viral resistance.

cdc.gov
In clinical practice and standard pharmacologic taxonomy, these therapeutics encompass anti-influenza agents that inhibit influenza virus replication, historically divided between selective viral M2 proton-channel blockers (adamantanes, active only against influenza A) and broad-spectrum influenza antivirals like neuraminidase inhibitors and cap-dependent endonuclease inhibitors (active against both influenza A and B) These agents are indicated for the prevention and treatment of acute uncomplic...
cdc.gov
In clinical practice and standard pharmacologic taxonomy, these therapeutics encompass anti-influenza agents that inhibit influenza virus replication, historically divided between selective viral M2 proton-channel blockers (adamantanes, active only against influenza A) and broad-spectrum influenza antivirals like neuraminidase inhibitors and cap-dependent endonuclease inhibitors (active against both influenza A and B)
cdc.gov
In clinical practice and standard pharmacologic taxonomy, these therapeutics encompass anti-influenza agents that inhibit influenza virus replication, historically divided between selective viral M2 proton-channel blockers (adamantanes, active only against influenza A) and broad-spectrum influenza antivirals like neuraminidase inhibitors and cap-dependent endonuclease inhibitors (active against both influenza A and B)
chicagohan.org
In clinical practice and standard pharmacologic taxonomy, these therapeutics encompass anti-influenza agents that inhibit influenza virus replication, historically divided between selective viral M2 proton-channel blockers (adamantanes, active only against influenza A) and broad-spectrum influenza antivirals like neuraminidase inhibitors and cap-dependent endonuclease inhibitors (active against both influenza A and B)
cdc.gov
These agents are indicated for the prevention and treatment of acute uncomplicated influenza viral infections and the management of epidemic outbreaks, although the clinical utility of M2 blockers has been largely superseded by widespread viral resistance
cdc.gov
These agents are indicated for the prevention and treatment of acute uncomplicated influenza viral infections and the management of epidemic outbreaks, although the clinical utility of M2 blockers has been largely superseded by widespread viral resistance